In clinical trial settings, Phase II studies (referenced via DOI 10.1210/jcem.83.2.4551) have examined MK-677 in the context of GH deficiency and muscle-wasting conditions, with particular interest in its IGF-1 normalizing effects in older populations
FDA has specifically flagged concerns with compounded injectable GLP-1 products, including: Nausea, vomiting, diarrhea, abdominal pain, and constipation Excessive dosing tied to titration mistakes, some serious enough to require hospitalization Concentration, measurement, labeling, and dosing considerations a mass-manufactured branded pen doesn't have in the same way A licensed provider needs to review your full medical history, current medications, and complete medication-specific risk information with you before treatment starts - this section is a prompt to have that conversation, not a substitute for it
Most GLP-1 side effects are manageable, and most of the people who quit early do so because no one helped them work through the first three months
In a 35-year-old, this is manageable